Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
7(37%)
Results Posted
50%(3 trials)
Terminated
2(11%)

Phase Distribution

Ph phase_2
5
26%
Ph phase_1
6
32%
Ph not_applicable
8
42%

Phase Distribution

6

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
6(31.6%)
Phase 2Efficacy & side effects
5(26.3%)
N/ANon-phased studies
8(42.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

6 of 10 finished

Non-Completion Rate

40.0%

4 ended early

Currently Active

7

trials recruiting

Total Trials

19

all time

Status Distribution
Active(7)
Completed(6)
Terminated(4)
Other(2)

Detailed Status

Recruiting7
Completed6
Terminated2
unknown2
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
19
Active
7
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (31.6%)
Phase 25 (26.3%)
N/A8 (42.1%)

Trials by Status

completed632%
recruiting737%
terminated211%
unknown211%
withdrawn211%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT07040956Phase 2

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

Recruiting
NCT06349837Phase 1

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Recruiting
NCT03352258Not Applicable

Effect of Low Dose Radiotherapy on Brain Amyloidosis in the Treatment of Alzheimer's Disease

Completed
NCT06610734Phase 2

Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)

Recruiting
NCT06494189Phase 1

Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

Completed
NCT06804850Phase 2

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

Withdrawn
NCT06887829Not Applicable

Radio- KO Radiotherapy for Knee Osteoarthritis Clinical Trial

Recruiting
NCT06848465Phase 1

LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis

Recruiting
NCT03812549Phase 1

Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients

Completed
NCT06331585Phase 2

Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy

Withdrawn
NCT05615142Phase 1

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

Recruiting
NCT04572412Not Applicable

Low Dose Lung Radiotherapy to Treat COVID-19 Pneumonia

Completed
NCT03196778Not Applicable

Low Dose Hemi-body Radiation For Recurrent Prostate Cancer

Completed
NCT03040804Not Applicable

Low Dose Radiotherapy for Advanced Hidradenitis Suppurativa

Terminated
NCT04904783Not Applicable

Low-Dose Radiation Therapy to Lungs in Moderate COVID-19 Pneumonitis: A Case-Control Pilot Study

Unknown
NCT03397810Not Applicable

Effect of Radiotherapy on ATTR Cardiac Amyloidosis : a Proof of Concept Study

Recruiting
NCT04534790Not Applicable

Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia

Completed
NCT04390412Phase 1

Low Dose Radiotherapy in COVID-19 Pneumonia

Unknown
NCT02254681Phase 2

Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC

Terminated

All 19 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
19